Figure 2 from Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib

<jats:p>&lt;p&gt;Expression of SLFN11, CD138, and Ki-67 in multiple myeloma (MM) patient samples and normal bone marrow. &lt;b&gt;A,&lt;/b&gt; Representative dual immunohistochemical staining for CD138 (blue, membrane) and SLFN11 (brown, nuclear) in bone marrow samples from patients with MM. Patients 1 and 2 are primary (P; newly diagnosed), whereas patient 3 (R) represents a sample from a recurrent patient. 81%–98% CD138-positive myeloma cells express SLFN11. &lt;b&gt;B,&lt;/b&gt; Dual immunohistochemical staining for CD138 (blue) and SLFN11 (brown) in normal bone marrow. Left, low magnification. Right, high magnification of the same field. Normal bone marrow contains 5.5%–6.8% plasma cells, of which 72%–85% demonstrate SLFN11 positivity, indicating that &lt;i&gt;SLFN11&lt;/i&gt; expression is an intrinsic feature of NPCs. Scale bars, 50 μm (left) and 10 μm (right). &lt;b&gt;C,&lt;/b&gt; Representative dual immunohistochemical staining for CD138 (blue) and Ki-67 (brown, nuclear) to assess proliferative activity. Left and middle, patient 1 at primary diagnosis (P) and third relapse (R3), respectively. Right, normal bone marrow. The PCPI, defined as the percentage of CD138-positive cells coexpressing Ki-67, is markedly elevated in myeloma specimens compared with normal bone marrow, with further increases observed at relapse. Scale bars, 10 μm. BM, bone marrow.&lt;/p&gt;</jats:p>